Castration-resistant prostate cancer (CRPC), the most lethal form of PCa is defined as radiological or biochemical progression (prostate-specific antigen (PSA) levels >2 ng/mL or PSA values >25% above nadir, or PSA elevation in three consecutive determinations at least one week apart) as long as suppressed testosterone levels (<50 ng/dL or 1.7 nmol/L) are confirmed [4]. The gene discussed is KLK3; the disease is posterior cortical atrophy.